000			02353 a2200661 4500
005			20250515174255.0
264		0	_c20101230
008			201012s 0 0 eng d
022			_a1559-131X
024	7		_a10.1007/s12032-009-9253-5 _2doi
040			_aNLM _beng _cNLM
100	1		_aDegirmenci, M
245	0	0	_aEfficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer. _h[electronic resource]
260			_bMedical oncology (Northwood, London, England) _cSep 2010
300			_a585-91 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAdenocarcinoma _xdrug therapy
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAngiogenesis Inhibitors _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aBevacizumab
650	0	4	_aCamptothecin _xadministration & dosage
650	0	4	_aCapecitabine
650	0	4	_aColonic Neoplasms _xdrug therapy
650	0	4	_aDeoxycytidine _xadministration & dosage
650	0	4	_aDisease-Free Survival
650	0	4	_aFatigue _xchemically induced
650	0	4	_aFemale
650	0	4	_aFluorouracil _xadministration & dosage
650	0	4	_aGastrointestinal Diseases _xchemically induced
650	0	4	_aHematologic Diseases _xchemically induced
650	0	4	_aHumans
650	0	4	_aHypertension _xchemically induced
650	0	4	_aIrinotecan
650	0	4	_aKaplan-Meier Estimate
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasm Proteins _xantagonists & inhibitors
650	0	4	_aRectal Neoplasms _xdrug therapy
650	0	4	_aRetrospective Studies
650	0	4	_aVascular Endothelial Growth Factor A _xantagonists & inhibitors
700	1		_aKaraca, B
700	1		_aGorumlu, G
700	1		_aDurusoy, R
700	1		_aDemir Piskin, G
700	1		_aBozkurt, M T
700	1		_aCirak, Y
700	1		_aTunali, D
700	1		_aKarabulut, B
700	1		_aSanli, U A
700	1		_aUslu, R
773	0		_tMedical oncology (Northwood, London, England) _gvol. 27 _gno. 3 _gp. 585-91
856	4	0	_uhttps://doi.org/10.1007/s12032-009-9253-5 _zAvailable from publisher's website
999			_c18945341 _d18945341